Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-randomized Phase 2 Study of Alvocidib (Flavopiridol) Plus Oxaliplatin With or Without 5-FU and Leucovorin for Relapsed or Refractory Germ-Cell Tumors

NCT00957905 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00957905
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00957905 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-randomized Phase 2 Study of Alvocidib (Flavopiridol) Plus Oxaliplatin With or Without 5-FU and Leucovorin for Relapsed or Refractory Germ-Cell Tumors
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2009
Completion date
August 31, 2014
Enrollment
36 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent extragonadal seminoma, recurrent malignant extragonadal germ cell tumor, recurrent malignant extragonadal non-seminomatous germ cell tumor, recurrent malignant testicular germ cell tumor, recurrent ovarian germ cell tumor, stage iii testicular cancer, stage iv extragonadal non-seminomatous germ cell tumor, stage iv extragonadal seminoma, stage iv ovarian germ cell tumor